Pfizer says pill to treat COVID-19 could be authorized by end of year or early 2022: 'It is a game changer'

Pfizer
(Image credit: Mario Tama/Getty Images)

Pfizer has announced that new data confirm its antiviral pill is effective at reducing the risk of hospitalization or death from COVID-19.

The company said Tuesday final trial results confirmed the antiviral pill reduced the risk of hospitalization or death for high-risk COVID-19 patients by 89 percent when given within three days of symptoms developing. This confirmed earlier data from a clinical trial. Pfizer executive Annaliesa Anderson previously told The New York Times that those results were "really beyond our wildest dreams."

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Brendan Morrow

Brendan worked as a culture writer at The Week from 2018 to 2023, covering the entertainment industry, including film reviews, television recaps, awards season, the box office, major movie franchises and Hollywood gossip. He has written about film and television for outlets including Bloody Disgusting, Showbiz Cheat Sheet, Heavy and The Celebrity Cafe.